Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "leukemia" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-15 z 49
Tytuł:
Analysis of dose distribution around a computed tomography scanner in terms of exposure to scattered ionizing radiation of caregivers of pediatric patients
Autorzy:
Biegała, Michał
Brodecki, Marcin
Skoczylas, Krystian
Jakubowska, Teresa
Domienik-Andrzejewska, Joanna
Powiązania:
https://bibliotekanauki.pl/articles/45912311.pdf
Data publikacji:
2024-09-10
Wydawca:
Instytut Medycyny Pracy im. prof. dra Jerzego Nofera w Łodzi
Tematy:
effective dose
radiological protection
leukemia
CT scanner
probability of induction of leukemia
pediatric radiology
Opis:
Objectives During computed tomography (CT), a large amount of ionizing radiation is emitted to ensure high quality of the obtained radiological image. This study measured the dose distribution around the CT scanner and the exposure of people staying near the CT scanner during the examination. Material and Methods The measurements used an anthropomorphic phantom to assess human exposure to ionizing radiation. The probability of inducing leukemia and other cancers as a result of absorbing doses recorded around the CT device was also calculated. Results The highest exposure to scattered radiation in the proximity of the CT scanner is recorded at the gantry of the tomograph, i.e., 55.7 μGy, and the lowest, below lower detection limit of 6 μGy at the end of the diagnostic table. The whole-body detector placed on the anthropomorphic phantom located at the diagnostic table right next to the CT gantry recorded 59.5 μSv and at the end of the table 1.5 μSv. The average doses to the lenses in these locations were: 32.1 μSv and 2.9 μSv, respectively. Conclusions The probability of induction of leukemia or other types of cancer is low, but the need for people to stay in the examination room during a CT examination should be limited to the necessary minimum.
Źródło:
International Journal of Occupational Medicine and Environmental Health; 2024, 37, 3; 326-334
1232-1087
1896-494X
Pojawia się w:
International Journal of Occupational Medicine and Environmental Health
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Comparison of the WHO classification (5th edition) 2022 and the International Consensus Classification (ICC) 2022 for diagnosis of acute myeloid leukemia
Autorzy:
Al-Nakkash, Naba
Frenzel, Lukas P.
Powiązania:
https://bibliotekanauki.pl/articles/35505928.pdf
Data publikacji:
2024
Wydawca:
Radomskie Towarzystwo Naukowe
Tematy:
AML
WHO
ICC
acute myeloid leukemia
World Health Organisation
International Consensus Classification
ostra białaczka szpikowa
Światowa Organizacja Zdrowia
Opis:
In 2022, two classifications were published to define the diagnosis of patients with acute myeloid leukemia (AML). The World Health Organisation (WHO) 5th edition and the International Consensus Classification (ICC) provide an updated summary of current knowledge of the diseases and construct a framework for physicians. Two differing classifications result in discrepancies, which change the definition of AML subtypes and present a challenge in clinical settings. This work summarizes the updated classification systems and discusses their significance in clinical settings while considering the latest findings. Relevant changes affect the i) required blast percentage, ii) AML harbouring CEBPA mutations, iii) AML with KMT2A and MECOM rearrangements, iv) AML with myelodysplasia-related characteristics and in association with this entity AML with mutated RUNX1, and lastly v) AML with TP53 mutation. In summary, a unified classification system would be desirable to achieve harmonized diagnosis and treatment of AML).
Źródło:
Scientiae Radices; 2024, 3, 1; 14-29
2956-4808
Pojawia się w:
Scientiae Radices
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Evaluating exposure-response relationship in 1,3-butadiene and leukemia studies
Autorzy:
Antoniou, Evangelia E.
Kirman, Chris
Powiązania:
https://bibliotekanauki.pl/articles/45904817.pdf
Data publikacji:
2024-09-10
Wydawca:
Instytut Medycyny Pracy im. prof. dra Jerzego Nofera w Łodzi
Tematy:
risk assessment
leukemia
exposure-response modelling
occupational cohort study
regulatory toxicology
3-butadiene
Opis:
Objectives 1,3-Butadiene (BD) exposure’s link to leukemia is under regulatory scrutiny. The assessment methods for BD exposure risks have evolved from early animal and limited human studies to advanced exposure-response modelling with comprehensive quantitative data. The objective of this study is to explore the nuances of exposure-response modelling, investigating how various statistical methods have influenced the quantification of exposure-response relationships. Material and Methods Although this study was not conducted as a formal systematic review, a search was performed in Medline/Pubmed to identify all human studies on leukemia risk assessment for BD exposure. This search included articles written in English. The electronic search spanned from inception of records until July 23, 2023, using the search term: “butadiene AND (leukaemia OR leukemia OR myeloid OR lymphoid)” and was restricted to human species. Focusing on the synthetic styrene-butadiene rubber (SBR) industry cohort study conducted by the University of Alabama at Birmingham, USA, this review evaluates various statistical models and factors influencing exposure-response modelling. Results Peak exposures to BD may be more influential in the dose-response relationship than cumulative or long-term exposure. The authors recommend utilizing β-coefficients derived from the latest SBR study update, employing Cox proportional hazard modelling, non-lagged and non-transformed cumulative BD exposure, and adjusting for age and peak BD exposure. The study reveals that statistical model selection has a limited impact on the calculated dose-response effects. The significant variation in estimated cancer mortality values arises from additional assumptions needed for metrics like the excess leukemia risk or the occupational BD effective concentration. Conclusions In conclusion, this study provides insights into exposure-response modelling for BD exposure and leukemia mortality, highlighting the importance of peak exposures. The recommended statistical approach offers a reliable basis for regulatory risk assessment and public health population metrics.
Źródło:
International Journal of Occupational Medicine and Environmental Health; 2024, 37, 3; 300-310
1232-1087
1896-494X
Pojawia się w:
International Journal of Occupational Medicine and Environmental Health
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Natural products as potential inhibitors of FLT3 for acute myeloid leukemia: HTVS, docking, and molecular dynamic simulation
Autorzy:
Salah, Salsabeel
Sami, Najat
Ali, Sarah
Khalid, Teemah-Alrahman
Alnajjar, Radwan
Powiązania:
https://bibliotekanauki.pl/articles/35500319.pdf
Data publikacji:
2023
Wydawca:
Radomskie Towarzystwo Naukowe
Tematy:
acute myeloid leukemia
drug design
anticancer
CADD
FLT3
ostra białaczka szpikowa
projektowanie leków
terapia antynowotworowa
Opis:
Cancer is one the most common health issues worldwide, with cancer-related mortality of 9.5 million in 2018, with an expectation to become 29.5 by 2040. Among others, acute myeloid leukemia (AML) is common among older people. FLT3 mutations are one of the most common genetic aberrations found in Acute Myeloid Leukemia and are associated with poor prognosis. Herein, we attempt to identify natural compounds as potential candidates to treat AML by targeting the FLT3 kinase domain using in silico approaches. The COCONUT database, which contains 407,270 natural compounds, was HTVS against the FLT3 kinase domain active site, and promising compounds were subject to molecular docking. Finally, frontier compounds were validated further using molecular dynamic simulation. In total, ten compounds were identified with docking scores higher than Quizartinib (-11.606 kcal/mol), with the best three compounds showing a docking score of -18.052, -15.772, and -16.767 kcal, respectively, and compound 2 showing excellent stability in molecular dynamic simulation.
Źródło:
Scientiae Radices; 2023, 2, 4; 325-346
2956-4808
Pojawia się w:
Scientiae Radices
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Aktywna postawa lekarza versus inercja pacjenta: wykrycie przewlekłej białaczki szpikowej podczas badań okresowych
Active physician attitude vs. patient inertia: detection of chronic myeloid leukemia during periodic examinations
Autorzy:
Marcinkiewicz, Andrzej
Powiązania:
https://bibliotekanauki.pl/articles/2152951.pdf
Data publikacji:
2022
Wydawca:
Instytut Medycyny Pracy im. prof. dra Jerzego Nofera w Łodzi
Tematy:
przewlekła białaczka szpikowa
wczesne wykrywanie
komunikacja lekarz–pacjent
stosowanie się do zaleceń lekarskich
udział pacjenta
zdrowie pracujących
chronic myeloid leukemia
early detection
physycian–patient communication
compliance
patient participation
occupational health
Opis:
Opis przypadku dotyczy zapoczątkowanego podczas badań okresowych postępowania profilaktyczno-orzeczniczego, które doprowadziło do wczesnego wykrycia przewlekłej białaczki szpikowej. Szczególną uwagę zwrócono na skrócenie terminu ważności badania okresowego uzasadnione nieprawidłowością w stanie zdrowia, która nie miała bezpośredniego związku z warunkami zawodowymi, oraz na sposób komunikacji i wpływ na pracownika, aby zastosował się do zaleceń lekarskich. Wywnioskowano, że wprawdzie obligatoryjne i cykliczne badania profilaktyczne do celów Kodeksu pracy stwarzają możliwość wczesnego wykrycia nieuświadomionych stanów chorobowych, dając tym samym szansę na poprawę stanu zdrowia pacjentów, ale jednocześnie mogą być traktowane jako ingerencja w prawo do samostanowienia jednostki o własnym życiu i zdrowiu. Uznano, że w ocenie sytuacji kluczowe są postawa lekarza medycyny pracy oraz sposób komunikacji z badanym pracownikiem, które nie tyle zmuszą, ile przekonają – dla dobra pacjenta – do podjęcia diagnostyki lub interwencji prozdrowotnej.
The case report concerns the prophylactic and medical certification procedure initiated during periodic examinations, which led to the early detection of chronic myeloid leukemia. Particular attention was paid to the shortening of the period of validity of the periodic examination, justified by an abnormal health condition that is not directly related to the working conditions, as well as the method of communication and influencing the employee to comply with medical recommendations. The conclusions stated that, although obligatory and periodic preventive examinations for the purposes of the Labor Code create the possibility of early detection of unawereness of disease, thus giving a chance to improve health, but at the same time they can be treated as an interference with the individual’s right to self-determination about his life and health. It was noted that the key factor in assessing the situation would be the attitude of the occupational medicine physician and the manner of his communication with the employee, who would not be forced, but convinced – for his benefit, to undertake diagnostics or health interventions.
Źródło:
Medycyna Pracy; 2022, 73, 6; 485-490
0465-5893
2353-1339
Pojawia się w:
Medycyna Pracy
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Leczenie przewlekłej białaczki limfocytowej (PBL) – - od przeszłości do teraźniejszości
Therapy of chronic lymphocytic leukemia (CLL) - from past to present
Autorzy:
Gumieniczek, Anna
Ciseł, Bogumiła
Lipska, Katarzyna
Filip, Agata A.
Powiązania:
https://bibliotekanauki.pl/articles/762589.pdf
Data publikacji:
2020-02-15
Wydawca:
Polskie Towarzystwo Farmaceutyczne
Tematy:
przewlekła białaczka limfocytowa (PBL)
chemioterapia
przeciwciała monoklonalne
allo-HSCT
terapia CAR-T
chronic lymphocytic leukemia (CLL)
chemotherapy
monoclonal antibodies
CAR-T therapy
Opis:
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in Western European countries. This disease occurs mainly in adult population at an age of over 50 years, more commonly in men. Many years of research have shown that CLL is a disease with a very diverse clinical course and variable sensitivity to treatment. Therefore, in each case of newly diagnosed CLL, the clinical stage, prognostic factors and individualized therapeutic goals should be precisely defined before the treatment initiation. Recent 50 years have been a period of significant development in the treatment of proliferative diseases of the hematopoietic and lymphatic systems. Along with dynamic development of molecular biology techniques, several new specific prognostic markers have been investigated and introduced, allowing better stratification of patients and more accurate direction of the therapy. A lot of effort has gone into searching for the next prognostic factors which allow to determine better probable life span and to implement the successful treatment. Furthermore, many preclinical and clinical studies continually extend the list of effective anticancer drugs, including these for CLL treatment. Increasingly, in addition to standard cytostatics, drugs with more selective mechanisms of action are being tested in monotherapy and new combinations. Considering the historical aspects, only a few anticancer drugs were available 50 years ago. In addition, they mainly presented the one mechanism of action directed at nucleic acids. Today, the list of effective drugs is significantly longer. In addition to typical cytostatics, it also contains drugs with selective mechanisms of action, affecting the cell life processes, their subcellular structures, signaling from outside and inside the cell, surface antigens, as well as drugs that act on the microenvironment of cancer cells and their vascularization. The aim of this paper was to show the historical background in the therapy of leukemia and summarize the current knowledge in CLL biology and treatments. The manuscript is focused on the clinical course of the disease, the main risk factors and mainly, on the available treatment strategies.
Przewlekła białaczka limfocytowa (PBL) jest najczęściej występującą postacią białaczki w krajach Europy Zachodniej. Jest to choroba dotycząca przede wszystkim osób powyżej 50 roku życia, częściej mężczyzn niż kobiet. Wieloletnie badania wykazały, że PBL jest chorobą o bardzo zróżnicowanym przebiegu klinicznym i zmiennej wrażliwości na zastosowane leczenie. W związku z powyższym, w każdym przypadku nowo zdiagnozowanej PBL, przed rozpoczęciem leczenia, należy precyzyjnie określić stadium zaawansowania klinicznego, czynniki prognostyczne oraz cele terapeutyczne zindywidualizowane dla danego pacjenta. Ostatnie 50 lat to okres istotnego postępu w leczeniu chorób rozrostowych układu krwiotwórczego i chłonnego. Wraz z dynamicznym rozwojem technik biologii molekularnej pojawiły się nowe, specyficzne czynniki prognostyczne, umożliwiające lepszą stratyfikację chorych oraz dokładniejsze określenie dalszego kierunku terapii. W dalszym ciągu prowadzone są prace nad kolejnymi czynnikami umożliwiającymi określenie długości przeżycia pacjenta oraz szans powodzenia terapii. Jednocześnie prowadzone badania przedkliniczne i kliniczne wydłużają listę bardziej skutecznych leków przeciwnowotworowych, znajdujących swoje zastosowanie również w PBL. Coraz częściej obok standardowych cytostatyków pojawiają się leki o bardziej swoistym mechanizmie działania, zarówno w monoterapii, jak i w nowych połączeniach. Celem pracy było przedstawienie rysu historycznego w zakresie terapii białaczek i przegląd dotychczasowej wiedzy na temat charakterystyki i terapii PBL. W artykule zwrócono szczególną uwagę na przebieg choroby, czynniki ryzyka oraz stosowane obecnie strategie leczenia.
Źródło:
Farmacja Polska; 2020, 76, 1; 47-56
0014-8261
2544-8552
Pojawia się w:
Farmacja Polska
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Partial remission in patient with Richter syndrome: an „emergency” treatment with pixantrone
Autorzy:
Szwedyk, Paweł
Powiązania:
https://bibliotekanauki.pl/articles/1035640.pdf
Data publikacji:
2020-06-30
Wydawca:
Medical Education
Tematy:
Richter syndrome
chemotherapy
chronic lymphocytic leukemia
immunotherapy
pixantrone
Opis:
Chronic lymphocytic leukemia is the most commonly recognized type of leukemia in adults. The appearance of systemic symptoms such as weight loss, fever, or local symptoms in the form of rapidly growing organomegaly, lymphadenopathy in a patient with CLL raises the suspicion of transformation into a high-grade lymphoma – defined as Richter syndrome which is usually associated with very poor prognosis. The described case concerns a 71-year-old patient with this diagnosis, in whom due to the confirmed resistance to subsequent lines of immuno- and chemotherapy, an „emergency” treatment with a modern chemotherapy drug from the aza-anthracendion group – pixantrone was used. Treatment with pixantrone was associated with a relatively good response, translating into partial remission (also in the area of infiltrative changes in the head and neck structures), stabilization of the course of the disease and, consequently, allowed to extend the patient’s life.
Źródło:
OncoReview; 2020, 10, 2; 52-56
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Rare case of Richter’s syndrome localization in liver and thyroid of a patient with a chronic lymphocytic leukemia (CLL) - case report and literature
Autorzy:
Wasik-Szczepanek, E.
Szymczyk, A.
Szczepanek, D.
Grywalska, E.
Szumiło, J.
Trojanowski, P.
Czabak, O.
Hus, M.
Powiązania:
https://bibliotekanauki.pl/articles/2085452.pdf
Data publikacji:
2020
Wydawca:
Instytut Medycyny Wsi
Tematy:
liver
thyroid
chronic lymphocytic leukemia
Richter’s syndrome
Opis:
Richter’s syndrome (RS) is a rare complication in which chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) transforms into a more aggressive type of lymphoma – diffuse large B cell lymphoma (DLBCL), or Hodgkin’s lymphoma (HL). The review describes the clinical case of a patient with CLL and RS diagnosis. A computed tomography (CT) scan of the abdominal cavity detected numerous normodense areas in the liver. Simultaneously, ultrasound examination (USG) of the thyroid revealed the presence of a solid hypoechogenic lump. The material sampled from closed biopsies of liver and thyroid in both cases allowed the diagnosis of diffuse large B cell lymphoma (DLBCL). The liver and the thyroid are particularly rare locations of RS. However, those cases allowed the conclusion that RS may occur even in a very unexpected and less probable location.
Źródło:
Annals of Agricultural and Environmental Medicine; 2020, 27, 1; 160-164
1232-1966
Pojawia się w:
Annals of Agricultural and Environmental Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
ANALYSIS OF CHRONIC MYELOID LEUKEMIA PHARMACOTHERAPY COSTS IN POLAND
Autorzy:
Paczkowska, Anna
Kus, Krzysztof
Nowicka, Monika
Kopciuch, Dorota
Zaprutko, Tomasz
Komarnicki, Mieczysław
Nowakowska, Elżbieta
Powiązania:
https://bibliotekanauki.pl/articles/895298.pdf
Data publikacji:
2019-02-28
Wydawca:
Polskie Towarzystwo Farmaceutyczne
Tematy:
poland
chronic myeloid leukemia
stem cell transplantation
pharmacotherapy cost analysis
Opis:
The aim of this study was to analyze pharmacotherapy cost of chronic myeloid leukemia from the society’s, the payer’s (National Health Fund), and the patient’s perspective. The study included 55 patients with a diagnosed and treated chronic myeloid leukemia at the selected hematology clinic in the city of Poznan. Retrospective study involved time horizon of one calendar year – 2013. The data required for economic evaluation were obtained from the patients’ case histories and the Department of Organization and Accounting of the selected health care facilities. The total cost of chronic myeloid leukemia pharmacotherapy for 55 patients from the society’s perspective in 2013 amounted to 1,483,416.88 EUR. Average annual cost of medication per patient in 2013 amounted to 26,971.22 EUR (Median – 32,854.22 EUR). Average cost of chronic myeloid leukemia pharmacotherapy for a patient without transplantation was 32,167.34 EUR (Median – 30,623.00 EUR), and for a patient after transplantation amounted to 413.13 EUR (Median – 378.40 EUR). The cost from the payer’s perspective is 99.93% of total costs from the society’s perspective. The cost from the patient’s perspective represents 0.07% of the total cost of chronic myeloid leukemia pharmacotherapy from the society’s perspective. Costs of chronic myeloid leukemia pharmacotherapy are very high and represent a significant burden to society. The highest costs associated with treatment of chronic myeloid leukemia are incurred by the society, and, subsequently, the public payer (NHF), and the patient.
Źródło:
Acta Poloniae Pharmaceutica - Drug Research; 2019, 76, 1; 175-183
0001-6837
2353-5288
Pojawia się w:
Acta Poloniae Pharmaceutica - Drug Research
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Mucormycosis in a patient with acute myeloblastic leukemia following liver transplantation for Wilson’s disease
Autorzy:
Łanocha, A.A.
Guzicka-Kazimierczak, R.
Zdziarska, B.
Wawrzynowicz-Syczewska, M.
Powiązania:
https://bibliotekanauki.pl/articles/2085182.pdf
Data publikacji:
2019
Wydawca:
Instytut Medycyny Wsi
Tematy:
Mucormycosis
acute myeloblastic leukemia
Willson’s disease
liver transplantation
Opis:
A case is presented of mucormycosis in a patient with acute myeloblastic leukemia following liver transplantation for Wilson’s disease. A 58-year-old female was admitted to the Department of Haematology with deterioration of her general condition, loss of appetite, tiredness and difficulty with mental contact for a few days. Blood and urine cultures for bacteria and fungus, galactomannan antigen were negative. Whole body computed tomography demonstrated bilateral hilar lymphadenopathy with necrotic lesions: splenomegaly with a hypodensive lesion 13 × 20 × 19 mm and lower pulmonary infiltrates suggested fungal etiology. Magnetic resonance imaging of the brain showed thickened meninges. Finally, mucormycosis was diagnosed. Treatment with amphotericin B lipid complex was started, resulting in an partial improvement of the general condition and decreased level of inflammatory markers. However, the patient’s condition continued to deteriorate, with sepsis etiology Escherichia coli, and despite the intensive managements she eventually died.
Źródło:
Annals of Agricultural and Environmental Medicine; 2019, 26, 4; 665-668
1232-1966
Pojawia się w:
Annals of Agricultural and Environmental Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
The effect of tyrosine kinase inhibitors used in the treatment of chronic myeloid leukemia on the cardiovascular system
Autorzy:
Sacha, Tomasz
Góra-Tybor, Joanna
Szmit, Sebastian
Powiązania:
https://bibliotekanauki.pl/articles/1035757.pdf
Data publikacji:
2019
Wydawca:
Medical Education
Tematy:
cardiovascular toxicity
chronic myeloid leukemia
tyrosine kinase inhibitors
Opis:
The use of tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid leukemia has significantly improved the prognosis and outcomes for most patients. Clinical trials indicate that long-term CML therapy requires the introduction of second- or third-generation inhibitors in approximately 40–50% of cases. Effective in the case of imatinib resistance or intolerance, second generation TKI’s can also be used as a first-line treatment, leading to a faster, and deeper molecular response. TKIs, however, have also been observed to cause significant late adverse effects, including cardiovascular complications, which may raise certain safety concerns. The excellent treatment outcomes achieved with tyrosine kinase inhibitors have led to a gradual increase in the number and age of treated patients, and the associated higher incidence and severity of age-related co-morbidities such as diabetes, hypercholesterolemia, atherosclerosis, ischemic heart disease, hypertension, and congestive heart failure, which raise the risk of treatment-related cardiovascular complications. The article discusses the effects of individual TKIs on the pathogenesis of cardiovascular complications and presents the results of clinical trials that studied their impact on the incidence of such events.
Źródło:
OncoReview; 2019, 9, 1; 3-21
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Assessment of the efficacy of ofatumumab in patients with chronic lymphocytic leukaemia treated in the Department of Haematooncology and Bone Marrow Transplantation of the Medical University in Lublin - prelimary results
Autorzy:
Wasik-Szczepanek, E.
Szymczyk, A.
Kowal, M.
Nogalski, A.
Hus, M.
Powiązania:
https://bibliotekanauki.pl/articles/2081565.pdf
Data publikacji:
2018
Wydawca:
Instytut Medycyny Wsi
Tematy:
chronic lymphocytic leukemia
ofatumumab
monoclonal antibodies
immunotherapy
Opis:
Introduction. Despite significant recent advances in the treatment of chronic lymphocytic leukaemia (CLL), most cases of the disease are still incurable. Treatment with monoclonal antibodies, such as ofatumumab, is one of the new therapeutic options. Objective. Retrospective analysis of the efficacy of ofatumumab in patients with chronic lymphocytic leukaemia (CLL) treated in the Haematooncology and Bone Marrow Transplantation Department of the Medical University of Lublin, Poland, during 2011–2013. Materials and method. The analysis included 5 patients (3 women and 2 men), aged 47–65, with Rai stage II-IV CLL, after a few lines of treatment. Three patients received ofatumumab in monotherapy and 2 patients received ofatumumab in combination with cyclophosphamide (50 mg/day) and dexamethasone (40 mg/day). All patients included in the study were diagnosed with an active form of leukaemia with symptoms such as lymphocytosis or massive lymphadenopathy. Results. All patients responded to the treatment. Within the first 8 weeks of the treatment, levels of white blood cells returned to normal in patients with baseline lymphocytosis (3 patients). An increase in platelet levels was reported in 3 patients. Haemoglobin levels were higher or comparable to the baseline values in all studied patients after the completion of immunotherapy. In the patient with massive lymphadenopathy and hepato- and splenomegaly, the size of the lymph nodes, spleen and liver decreased and neutrophil levels increased. Time of progression was 5–12 months, and in one patient partial remission has been maintained. The treatment was well-tolerated in most cases. Asymptomatic neutropenia and an infection with Candida glabrata were observed. Conclusions. Ofatumumab may be a new and safe therapeutic option for patients with CLL after a few lines of treatment.
Źródło:
Annals of Agricultural and Environmental Medicine; 2018, 25, 1; 56-59
1232-1966
Pojawia się w:
Annals of Agricultural and Environmental Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Cytotoxic, Genotoxic and Apoptotic Activity of Isolated Compound from Pandanus odorattissimus
Autorzy:
Kamble, Abhaykumar
Swamy, Paramjyothi
Powiązania:
https://bibliotekanauki.pl/articles/1161866.pdf
Data publikacji:
2018
Wydawca:
Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
Tematy:
Apoptotic activity
Comet assay
Cytotoxic activity
Human Leukemia 60 (HL-60) cells
Pandanus odorattissimus L
Opis:
The present study reports potential activities like cytotoxic, genotoxic and apoptotic activity of phenolic compound 4-(4-(3,4-dimethoxyphenyl)hexahydrofuro[3,4-c]furan-1-yl)-2-methoxyphenyl acetate isolated from methanolic extract of Pandanus odorattissimus. The compound showed a significant cytotoxic effect on Human Leukemia 60 (HL-60) cell line. Exposure of the compound reduced the viability of HL-60 cells after 12, 24 and 48 hours, the compound exerted a significant cytotoxic effect on HL-60 cells. The compound also induced significant DNA damage. The results of comet assay with pattern of the HL-60 cells has shown an intact head and complete absence of DNA fragments in the form of tail suggesting that the doses are not genototoxic. The phenolic compound at concentration of 20 µg/mL, showed an increase in percentage tail of DNA upto 6.21 units when compared to control 5.35. Although all of the compound induced significant DNA damage it induced apoptotic in the middle level and led to significant level. Apoptotic effect of compound on HL-60 cells after 72 h increased. Furthermore, the compound induced slight necrosis in HL-60 cells. Although the compound induced significant DNA damage, it induced apoptotic at the middle level. Apoptotic effect of compound on HL cells after 72 hrs increased level, furthermore the compound induced slight necrosis in HL-60 cells.
Źródło:
World Scientific News; 2018, 112; 193-206
2392-2192
Pojawia się w:
World Scientific News
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Czy galusan epigallokatechiny może być skutecznym polifenolem w terapii skojarzonej z etopozydem w leczeniu przewlekłej białaczki szpikowej?
Can epigallocatechin gallate be an effective polyphenol in combination therapy with etoposide for the treatment of chronic myelogenous leukemia?
Autorzy:
Cierniak, Agnieszka
Skubal, Magdalena
Kalemba-Drożdż, Małgorzata
Powiązania:
https://bibliotekanauki.pl/articles/970179.pdf
Data publikacji:
2018
Wydawca:
Krakowska Akademia im. Andrzeja Frycza Modrzewskiego
Tematy:
apoptoza
EGCG
etopozyd
przewlekła białaczka szpikowa
uszkodzenia DNA
apoptosis
etoposide
chronic myeloid leukemia
DNA damage
Opis:
Wprowadzenie: Składnik zielonej herbaty – galusan epigallokatechiny (EGCG) – znany jest ze swoich właściwości chemoprewencyjnych i chemoterapeutycznych. Wykazuje silne właściwości antyoksydacyjne i przeciwzapalne, a w stosunku do komórek nowotworowych – działanie antyproliferacyjne lub proapoptotyczne. Etopozyd jest jednym z najczęściej stosowanych leków przeciwnowotworowych, wywołującym jednak wiele skutków ubocznych. Materiały i metody: W eksperymentach in vitro badano potencjalną rolę EGCG w terapii skojarzonej z etopozydem w leczeniu przewlekłej białaczki szpikowej. Komórki ustalonej linii białaczkowej K562 poddano działaniu etopozydu i/lub EGCG w celu określenia wpływu EGCG na przeżywalność komórek, poziom uszkodzeń DNA oraz częstość procesu apoptozy. Poziom uszkodzeń DNA mierzono przy pomocy elektroforezy pojedynczych komórek w żelu agarozowym (test kometowy), natomiast apoptozę oceniano pod mikroskopem fluorescencyjnym z użyciem barwnika Hoechst 33342. Wyniki: Uzyskane wyniki badań wskazują, że EGCG w stężeniu 50 i 100 μM uwrażliwia komórki białaczkowe na cytotoksyczne działanie etopozydu, zwiększając poziom uszkodzeń DNA i częstość apoptozy. Wnioski: Dane wskazują, że galusan epigallokatechiny może się okazać skutecznym polifenolem w terapii skojarzonej z etopozydem w leczeniu przewlekłej białaczki szpikowej
Introduction: Green tea ingredient – epigallocatechin gallate (EGCG) – is known for its chemopreventive and chemotherapeutic properties. It has strong antioxidant and anti-inflammatory properties, and antiproliferative or pro-apoptotic activity against cancer cells. Etoposide is one of the most commonly used anti-cancer drugs causing many side effects. Materials and methods: This study investigated the role of EGCG in combination therapy with etoposide in the treatment of chronic myeloid leukemia. K562 cells were treated with EGCG and / or etoposide to determine the effect of this polyphenol on cell survival, DNA damage or apoptosis. DNA damages were measured with single cell gel electrophoresis (comet assay) and the apoptosis were analyzed in fluorescence microscope with Hoechst 33342 staining. Results: Preliminary results suggest that EGCG at 50 and 100 μM sensitizes leukemic cells to the cytotoxic effect of etoposide, increases DNA damage that promotes removal cell and directs them to apoptosis. Conclusions: The data show that epigallocatechin gallate may prove to be an effective polyphenol in combination therapy with etoposide in the treatment of chronic myeloid leukemia. However, further research is needed to explain the EGCG interaction with chemotherapeutics.
Źródło:
Państwo i Społeczeństwo; 2018, 3; 9-28
1643-8299
2451-0858
Pojawia się w:
Państwo i Społeczeństwo
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Nursing care of a child with acute lymphoblastic leukemia
Autorzy:
Ślifirczyk, A.
Piszcz, P.
Ślifirczyk, M.
Michalczuk, T.
Urbańczuk, M.
Celiński, M.
Bytys, M.
Domańska, D.
Nikoniuk, M.
Powiązania:
https://bibliotekanauki.pl/articles/1918640.pdf
Data publikacji:
2018
Wydawca:
Uniwersytet Medyczny w Białymstoku
Tematy:
Acute lymphoblastic leukemia
cancer
care
Opis:
Every year a very large number of children in the world suffer from acute lymphoblastic leukemia, and for years there has been a steady increase in the number of new cases. Acute lymphoblastic leukemia accounts for 75% of leukemia cases in the world. Lymphoblastic leukemia is a cancer disease that originates in B or T cell lymphocytes, which expansion takes place in blood and in the bone marrow. The etiology of the disease is not fully understood because it consists of several factors conditioning its formation. The most important element is the early detection and taking actions resulting in effective disease control through treatment and care of the patient. The nursing process should allow the patient to be involved in and accept the ongoing cancer process, and medical personnel, family and specialists in such fields as psychology and psychiatry should participate.
Źródło:
Progress in Health Sciences; 2018, 8(2); 168-173
2083-1617
Pojawia się w:
Progress in Health Sciences
Dostawca treści:
Biblioteka Nauki
Artykuł
Wyświetlanie 1-15 z 49

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies